A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk

Breast Cancer Research and Treatment

Volumn 142, Issue 2, 2013, Pages 389-398

  Vinayak, Shaveta ^a   Schwartz, Erich J ^a   Jensen, Kristin ^a   Lipson, Jafi ^a   Alli, Elizabeth ^a   McPherson, Lisa ^a   Fernandez, Adrian M ^a   Sharma, Vandana B ^a   Staton, Ashley ^a   Mills, Meredith A ^a   Schackmann, Elizabeth A ^a   Telli, Melinda L ^a   Kardashian, Ani ^a   Ford, James M ^a   Kurian, Allison W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; BRCA1 2; Breast cancer; Cancer prevention; Cancer risk reduction; Clinical trial; Lovastatin; Random periareolar fine needle aspiration

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; C REACTIVE PROTEIN; CHOLESTEROL; DNA; ESTROGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UVOMORULIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BREAST AREOLA; BREAST CANCER; BREAST DUCT; CANCER RISK; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOPATHOLOGY; DISEASE ASSOCIATION; DNA DAMAGE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DYSPEPSIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEASIBILITY STUDY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; GENOTYPE; GERM LINE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LIPID BLOOD LEVEL; LIPID PEROXIDATION; MAMMOGRAPHIC DENSITY; MAMMOGRAPHY; MIDDLE AGED; MYALGIA; OXIDATIVE STRESS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK REDUCTION; SAMPLE SIZE; SINGLE BLIND PROCEDURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTICARCINOGENIC AGENTS; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; C-REACTIVE PROTEIN; DEOXYGUANOSINE; DNA DAMAGE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; LIPID PEROXIDATION; LIPIDS; LOVASTATIN; MAMMARY GLANDS, HUMAN; MIDDLE AGED; OXIDATIVE STRESS; PATIENT COMPLIANCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84890434811     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2739-z     Document Type: Article

References (47)

1. American Cancer Society: Cancer Facts and Figures (2013) http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/ cancer-facts-figures-2013. Accessed Jan 2013
2. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19(8):1893-1907. doi: 10.1158/1055-9965.EPI-10-0437
3. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371-1388
4. Li Y, Brown PH (2007) Translational approaches for the prevention of estrogen receptor-negative breast cancer. Eur J Cancer Prev 16(3):203-215. doi: 10.1097/CEJ.0b013e328011ed9800008469-200706000-00007
5. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727-2741. doi: 10.1001/jama.295.23.joc60074
6. Fabian CJ, Kimler BF, Mayo MS, Khan SA (2005) Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer 12(2):185-213. doi: 10.1677/erc.1.01000
7. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267-1278. doi: 10.1016/S0140-6736(05)67394-1
8. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC (2006) Breast cancer growth prevention by statins. Cancer Res 66(17):8707-8714. doi: 10.1158/0008-5472.CAN-05-4061
9. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, Paskett ED, Vitolins MZ, Furberg CD, Chlebowski RT (2006) Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst 98(10):700-707. doi: 10.1093/jnci/djj188
10. Heikkila K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, Ben-Shlomo Y, Ebrahim S, Lawlor DA (2009) Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20(1):15-26. doi: 10.1007/s10552-008-9212-z
11. Zhang SM, Lin J, Cook NR, Lee IM, Manson JE, Buring JE, Ridker PM (2007) C-reactive protein and risk of breast cancer. J Natl Cancer Inst 99(11):890-894. doi: 10.1093/jnci/djk202
12. Key TJ, Appleby PN, Reeves GK, Roddam AW (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11(6):530-542. doi: 10.1016/S1470-2045(10)70095-4
13. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB (2010) Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49(11):1603-1616. doi: 10.1016/j.freeradbiomed.2010.09.006
14. Cooke MS, Olinski R, Evans MD (2006) Does measurement of oxidative damage to DNA have clinical significance? Clin Chim Acta 365(1-2):30-49. doi: 10.1016/j.cca.2005.09.009
15. Olinski R, Rozalski R, Gackowski D, Foksinski M, Siomek A, Cooke MS (2006) Urinary measurement of 8-OxodG, 8-OxoGua, and 5HMUra: a noninvasive assessment of oxidative damage to DNA. Antioxid Redox Signal 8(5-6):1011-1019. doi: 10.1089/ars.2006.8.1011
16. Ziv E, Shepherd J, Smith-Bindman R, Kerlikowske K (2003) Mammographic breast density and family history of breast cancer. J Natl Cancer Inst 95(7):556-558
17. Lee MM, Petrakis NL, Wrensch MR, King EB, Miike R, Sickles E (1994) Association of abnormal nipple aspirate cytology and mammographic pattern and density. Cancer Epidemiol Biomarkers Prev 3(1):33-36
18. Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CH, Ferraro JA, Zalles CM, Stanton AL, Masood S, Grizzle WE, Boyd NF, Arneson DW, Johnson KA (2002) A phase II breast cancer chemoprevention trial of oral alpha- difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 8(10):3105-3117
19. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, Yaffe MJ (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med 356(3):227-236. doi: 10.1056/NEJMoa062790
20. Claus EB, Risch N, Thompson WD (1994) Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73(3):643-651
21. Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101(15):1058-1065. doi: 10.1093/jnci/djp181
22. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649-655
23. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75-89
24. Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Kamel S, Zeiger S, Mayo MS (2000) Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 92(15):1217-1227
25. Masood S (2005) Cytomorphology of fibrocystic change, high-risk proliferative breast disease, and premalignant breast lesions. Clin Lab Med 25(4):713-731, vi. doi: 10.1016/j.cll.2005.08.005
26. Lipkin SM, Chao EC, Moreno V, Rozek LS, Rennert H, Pinchev M, Dizon D, Rennert G, Kopelovich L, Gruber SB (2010) Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila) 3(5):597-603. doi: 10.1158/1940-6207.CAPR-10-0007
27. American College of Radiology (2003) ACR BI-RADS breast imaging and reporting data system: breast imaging atlas, 4th edn. American College of Radiology, Reston
28. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ (1994) The quantitative analysis of mammographic densities. Phys Med Biol 39(10):1629-1638
29. Heine JJ, Carston MJ, Scott CG, Brandt KR, Wu FF, Pankratz VS, Sellers TA, Vachon CM (2008) An automated approach for estimation of breast density. Cancer Epidemiol Biomarkers Prev 17(11):3090-3097. doi: 10.1158/1055-9965.EPI- 08-0170
30. Cauley JA, Zmuda JM, Lui LY, Hillier TA, Ness RB, Stone KL, Cummings SR, Bauer DC (2003) Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 12(8):749-756. doi: 10.1089/154099903322447710
31. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM (2006) Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 24(30):4808-4817. doi: 10.1200/JCO.2006.06.3560
32. Browning DR, Martin RM (2007) Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120(4):833-843. doi: 10.1002/ijc.22366
33. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM (2006) Statins and cancer risk: a meta-analysis. JAMA 295(1):74-80. doi: 10.1001/jama.295.1.74
34. Kuoppala J, Lamminpaa A, Pukkala E (2008) Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 44(15):2122-2132. doi: 10.1016/j.ejca.2008.06.025
35. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ (2008) Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev 17(5):1028-1033. doi: 10.1158/1055-9965.EPI-07-0726
36. Pocobelli G, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Egan KM (2008) Statin use and risk of breast cancer. Cancer 112(1):27-33. doi: 10.1002/cncr.23129
37. Woditschka S, Habel LA, Udaltsova N, Friedman GD, Sieh W (2010) Lipophilic statin use and risk of breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 19(10):2479-2487. doi: 10.1158/1055-9965.EPI-10-0524
38. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ (2010) Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat 119(1):137-144. doi: 10.1007/s10549-009-0507-x
39. Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, Jeter SC, Armstrong DK, Davidson NE, Emens LA, Fetting JH, Powers PP, Wolff AC, Green H, Thibert JN, Rae JM, Folkerd E, Dowsett M, Blumenthal RS, Garber JE, Stearns V (2012) A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat 131(3):915-924. doi: 10.1007/s10549-011-1858-7
40. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364(25):2381-2391. doi: 10.1056/NEJMoa1103507
41. Brenner DE, Hawk E (2013) Trials and tribulations of interrogating biomarkers to define efficacy of cancer risk reductive interventions. Cancer Prev Res (Phila) 6(2):71-73. doi: 10.1158/1940-6207.CAPR-12-0499
42. Fabian CJ, Zalles C, Kamel S, McKittrick R, Moore WP, Zeiger S, Simon C, Kimler B, Cramer A, Garcia F et al (1993) Biomarker and cytologic abnormalities in women at high and low risk for breast cancer. J Cell Biochem Suppl 17G:153-160
43. Fabian CJ, Zalles C, Kamel S, Zeiger S, Simon C, Kimler BF (1997) Breast cytology and biomarkers obtained by random fine needle aspiration: use in risk assessment and early chemoprevention trials. J Cell Biochem Suppl 28-29:101-110
44. Waters EA, Cronin KA, Graubard BI, Han PK, Freedman AN (2010) Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev 19(2):443-446. doi: 10.1158/1055-9965.EPI-09-0930
45. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH (2003) Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 95(7):526-532
46. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H (2011) Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 12(5):496-503. doi: 10.1016/S1470-2045(11)70030-4
47. Meyskens FL Jr, Curt GA, Brenner DE, Gordon G, Herberman RB, Finn O, Kelloff GJ, Khleif SN, Sigman CC, Szabo E (2011) Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res (Phila) 4(3):311-323. doi: 10.1158/1940-6207.CAPR-09- 0014